Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options
Brief Summary: The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (DMARDs) approved for rheumatoid arthritis (RA) in subjects with active RA. Secondary objectives assessed the clinical efficacy of combination treatment, including disease activity, physical function, and quality of life outcomes.


Options:
A: Arm Label: Placebo Plus Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Other: Placebo | Arm Label: Rituximab plus Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: MabThera/Rituxan, Drug: Methotrexate | Intervention Type: DRUG; Name: MabThera/Rituxan; Assigned to Arm(s): Rituximab plus Methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Placebo Plus Methotrexate, Rituximab plus Methotrexate | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Plus Methotrexate
B: Arm Label: Rituximab (0.5 g x 2) + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: rituximab | Arm Label: Rituximab (1.0 g x 2) + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: rituximab | Arm Label: Placebo + Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: placebo | Intervention Type: DRUG; Name: folate; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo + Methotrexate | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate
C: Arm Label: Open-label Abatacept (ABA)-Previous User; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Arm Label: Open-label ABA-Current User; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Drug: Anti-Tumor Necrosing Factor (TNF) Therapy | Arm Label: Long-term ABA; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Long-term ABA, Open-label ABA-Current User, Open-label Abatacept (ABA)-Previous User | Intervention Type: DRUG; Name: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD); Assigned to Arm(s): Long-term ABA, Open-label ABA-Current User, Open-label Abatacept (ABA)-Previous User | Intervention Type: DRUG; Name: Anti-Tumor Necrosing Factor (TNF) Therapy; Assigned to Arm(s): Open-label ABA-Current User
D: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol

Answer: C